Clinical Trial of Thrombectomy Systems (NCT07749820) | Clinical Trial Compass
RecruitingNot Applicable
Clinical Trial of Thrombectomy Systems
China167 participantsStarted 2026-08-30
Plain-language summary
This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years；
* Confirmed lower extremity deep vein thrombosis (DVT) by imaging, meeting at least one of the following: (1) acute iliofemoral or femoropopliteal DVT; or (2) subacute iliofemoral DVT;
* Investigator-assessed life expectancy ≥1 year;
* Willing to participate in this study and provide written informed consent.
Exclusion Criteria:
* Infection at the puncture site or severe systemic infection;
* Inability to establish vascular access or difficulty in advancing the guidewire through the lesion;
* Hemodynamically unstable pulmonary embolism;
* The target lesion thrombosis is recurrent after prior interventional therapy;
* A venous stent has been implanted in the target lesion, or the presence of an inferior vena cava filter that interferes with device deployment;
* Bilateral lower extremity deep vein thrombosis requiring thrombectomy in the same procedure;
* Active bleeding within the past 30 days, including severe intracranial, gastrointestinal, or urinary tract bleeding;
* History of hemorrhagic or ischemic stroke within the past 30 days;
* Known severe coagulation disorder or bleeding tendency;
* Severe hepatic or renal impairment;
* Known allergy or significant hypersensitivity to iodine-based contrast media, thrombolytic agents, anticoagulants, or antiplatelet drugs;
* Known conditions such as severe hyperthyroidism, multiple myeloma, or severe heart failure that preclude tolerance to percutaneous transluminal angioplasty;
* Pregnant or…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.